From: A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects
G1
G2
G3
G4
N0 of patients
At 6 months (subacute)
Hyperpigmentation
22 (34%)
4 (6%)
0
65
At 12 months
Fibrosis
28 (43%)
2 (3%)
3 (5%)
At 24 months*
25 (45%)
56